Boston Children’s Hospital is home to the world’s most extensive research enterprise at a pediatric hospital.
Atopic dermatitis research
The Atopic Dermatitis Center, a program within the Division of Immunology at Boston Children’s, develops treatments informed by research. Lynda Schneider, MD, is a principal investigator for a study sponsored by Regeneron Pharmaceuticals Inc. investigating the safety and efficacy of dupilumab in treating moderate to severe atopic dermatitits (AD), also commonly known as eczema, in patients aged 6 months to under 6 years of age.
The Boston Children’s Hospital Asthma Clinical Research Center is conducting a research study called Mechanisms of Increased Disease Severity in Atopic Dermatitis patients. The study is for people ages 6 to 65 and is funded by the National Institutes of Health. The goal of the study is to look at gene expression in both affected and unaffected sites of skin. This study may not have direct benefit to you but it will help us better understand if certain genetic factors lead to more severe atopic dermatitis or eczema. The lead investigator of the study is Dr. Wanda Phipatanakul, and Drs. Lynda Schneider and Raif Geha are co-investigators. Anyone interested in this study can email: asthma-dl@childrens.harvard.edu or call 857-218-5336.
Marilyn Liang, MD, is a dermatologist and principal investigator in a study called “The Impact of Pediatric Skin Disorders: The 'Big' Study,” sponsored by The Pediatric Dermatology Research Alliance. This study seeks to understand the severity and the type of stigma experienced across different kinds of skin conditions, helping to identify methods of intervention to lessen the impact of skin disorders.
Food allergy research
Dr. Schneider and Dr. Rima Rachid are conducting studies to evaluate desensitization for peanut allergy in children and young adults.
If you or your child are interested in participating in any of the studies mentioned here, please contact 617-355-6127.